Patent: 10,004,694
✉ Email this page to a colleague
Summary for Patent: 10,004,694
Title: | Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same |
Abstract: | Provided are a poorly water-soluble drug delivery system, a method of preparing the same, a method of delivering a poorly water-soluble drug using the same, and a pharmaceutical composition including the same as an effective component, and more particularly, a poorly water-soluble drug delivery system aiming cancer cell specific targeting, which may variously control the kind of a cancer cell targeting material capable of specifically reacting to an antigen overexpressed in a cancer cell, thereby binding to the surface of the poorly water-soluble drug delivery system, and variously control the kind of a poorly water-soluble drug encapsulated therein depending on the kind of cancer and a therapeutic purpose, thereby being effectively applicable to a cancer treatment method. |
Inventor(s): | Park; Keunchil (Seoul, KR), Kim; Jin-Ho (Icheon, KR), Kim; Youngwook (Seongnam, KR), Bae; Ki Hyun (Bukit Batok, SG) |
Assignee: | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) |
Application Number: | 14/427,361 |
Patent Claims: | see list of patent claims |
Details for Patent 10,004,694
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-09-12 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2032-09-12 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2032-09-12 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2032-09-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |